News
Dasatinib adds no survival benefit to docetaxel in mCRPC
Major finding: Overall survival was 21.5 months when dasatinib was added to docetaxel and prednisone and 21.2 months without dasatinib.Data source...
News
Aflibercept adds toxicity and no survival benefit in mCRPC
Major finding: Overall survival of patients in the aflibercept arm was 22.1 months, compared with 21.2 months in the placebo arm (HR = 0.94; P = ....
News
Abiraterone reduced morbidity in mCRPC patients
Major finding: The time of radiographic progression-free survival was doubled in patients given abiraterone and prednisone relative to those given...
Aesthetic Dermatology
Neurotic excoriation case treated successfully with onabotulinumtoxinA
News
RF positivity may predict response to some biologics in RA
Major Finding: In six studies of rituximab that used EULAR response criteria, patients with IgM RF positivity had significantly greater odds for...
